fda glp-1 warning letters november 2025 Beyond the Headlines: to Compounders FDA Issues Warning Letters to

A compound with a 30-minute half-life will reach undetectable plasma concentrations faster than one with a 3-hour half-life

Control type S2 meal type: F 1,4 = 0.13, p = 0.73, see also Fig

While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients, Chris Boshoff, chief scientific officer at Pizer, said in a statement

An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy